Journal
ONCOTARGET
Volume 8, Issue 2, Pages 2224-2232Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.13653
Keywords
cyclin B1; solid tumors; prognosis; overall survival; meta-analysis
Categories
Funding
- National Natural Science Foundation of China [81572800]
- Science and Technology Department of Zhejiang Province [2013c03044-7]
- Natural Science Foundation of Zhejiang Province [LY13H160016, LY15H160041]
Ask authors/readers for more resources
Cyclin B1 is a key mitotic cyclin in the G2-M phase transition of the cell cycle and is overexpressed in various malignant tumors. Numerous studies have reported contradictory evidences of the correlation between cyclin B1 expression and prognosis in human solid tumors. To address this discrepancy, we conducted a meta-analysis with 17 published studies searched from PubMed and Medline. Cyclin B1 overexpression was significantly associated with poor 3-year overall survival (OS) (OR = 2.05, 95% CI = 1.20 to 3.50, P = 0.009) and 5-year OS (OR = 2.11, 95% CI = 1.33 to 3.36, P = 0.002) of solid tumors. Subgroup analysis revealed that elevated cyclin B1 expression was associated with worse prognosis of lung cancer and esophageal cancer but better prognosis of colorectal cancer. In summary, overexpression of cyclin B1 is correlated with poor survival in most solid tumors, which suggests that the expression status of cyclin B1 is a significant prognostic parameter in solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available